Get the Stockscreener App
1.86
6.90%
0.12
After Hours:
1.87
0.01
+0.54%
Gain Therapeutics Inc Stock (GANX) Latest News
The 3.8% return this week takes United Therapeutics' (NASDAQ:UTHR) shareholders five-year gains to 314% - Yahoo Finance
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Increase in Short Interest - MarketBeat
HC Wainwright Lifts Earnings Estimates for Gain Therapeutics - Defense World
HC Wainwright Reaffirms “Buy” Rating for Gain Therapeutics (NASDAQ:GANX) - Defense World
Stock market today: Poseida Therapeutics +224.30%, Primega Group Holdings +98.77% among the top gainers in early trading - Business Upturn
Gain Therapeutics shares hold Buy rating; H.C. Wainwright optimistic on GT-02287 clinical data - Investing.com Canada
FY2024 Earnings Forecast for GANX Issued By Chardan Capital - Defense World
FATE Presents Encourgaing Data From Lupus Study, Stock Gains - Nasdaq
Stock Market News: Aclaris Therapeutics gains over 55% while Exicure increases almost 31% during mid day trading - Business Upturn
Stock market news: Renewable Japan jumps nearly 69% by mid-day, D. Western Therapeutics and Agile Media Network post strong gains - Business Upturn
Gain Therapeutics Advances Parkinson’s Therapy Development - TipRanks
Stock market today: Fate Therapeutics gains 70.79% whereas SiNtx Technologies rose by 38.73% in early trading - Business Upturn
Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Up 15.1% in October - Defense World
Chesapeake Granite Wash Trust (OTCMKTS:CHKR) Sees Large Increase in Short Interest - Defense World
PDS Biotechnology’s (PDSB) Buy Rating Reiterated at HC Wainwright - Defense World
Tapestry (NYSE:TPR) Price Target Raised to $66.00 - Defense World
Protara Therapeutics, Inc. (NASDAQ:TARA) Sees Large Increase in Short Interest - MarketBeat
Gain Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Pre-market Movers: GANX, TFFP, AKYA, CLDI... - RTTNews
Gain Therapeutics Inc (GANX) Quarterly 10-Q Report - Quartz
Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update - The Manila Times
Gain Therapeutics' Parkinson's Drug Shows 53% Activity Boost in Phase 1 Trial | GANX Stock News - StockTitan
The Future Of Inflammation: The Inflammasome And Beyond - Citeline News & Insights
Insiders of Tectonic Therapeutic, Inc. (NASDAQ:TECX) were rewarded after last week’s 10% gain - Simply Wall St
Endeavour Silver Corp (EXK) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
Individual investors who hold 54% of Galectin Therapeutics Inc. (NASDAQ:GALT) gained 12%, insiders profited as well - Simply Wall St
2024's 10 Best-Performing Stocks | Investing - U.S News & World Report Money
CAMP4 Analyst Highlights Rare Disease Platform Potential - Benzinga
U.S. Stock market: Zoomcar Holdings (+192.21%), Avalon GloboCare (+56.73%), and Vimeo (+40.85%) experience significant gains during mid day trading - Business Upturn
Canada Market top gains:Q2 Metals Corp rises 17.00% while Valeura Energy climbs 15.55% at midday - Business Upturn
Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential - Yahoo Finance
Hoping for a weight-loss pill? It could get closer to reality next week. - MarketWatch
individual investors who own 55% along with institutions invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) saw increase in their holdings value last week - Yahoo Finance
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shares Bounce 27% But Its Business Still Trails The Industry - Simply Wall St
Amneal Pharmaceuticals (NASDAQ:AMRX) grows 3.0% this week, taking five-year gains to 211% - Yahoo Finance
Tarsus Pharmaceuticals (TARS) Surges 10.6%: Is This an Indication of Further Gains? - Yahoo Finance
Short Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Decreases By 12.6% - MarketBeat
Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
Nuclear stocks gain on AI optimism: Oklo, NuScale, Centrus - Yahoo Finance
Investing in Arcturus Therapeutics Holdings (NASDAQ:ARCT) five years ago would have delivered you a 76% gain - Yahoo Finance
Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2 - The Manila Times
What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling You - Simply Wall St
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Yahoo Finance
Gain Therapeutics Regains Nasdaq Compliance - Investing.com
Gain Therapeutics Regains Nasdaq Compliance By Investing.com - Investing.com UK
The Manufacturers Life Insurance Company Acquires 6,328 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider - MSN
32 NMEs gain US FDA clearance through Q3, approvals up over 2023 - BioWorld Online
Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know - MSN
How should investors view Janux Therapeutics Inc (JANX)? - US Post News
What was Gain Therapeutics Inc (GANX)’s performance in the last session? - US Post News
Gain Therapeutics Inc [GANX] Investment Guide: What You Need to Know - Knox Daily
GANX Stock: A Voyage Through Gain Therapeutics Inc’s Finances - The InvestChronicle
Can you now get a good deal on Compass Therapeutics Inc’s shares? - US Post News
Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - The Manila Times
Renaissance Technologies LLC Boosts Holdings in Exagen Inc. (NASDAQ:XGN) - Defense World
Renaissance Technologies LLC Has $152,000 Stock Position in Gain Therapeutics, Inc. (NASDAQ:GANX) - Defense World
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):